Differential role of sarcolemmal and mitochondrial KATP channels in ...

Am J Physiol Heart Circ Physiol 279: H2694–H2703, 2000.

Differential role of sarcolemmal and mitochondrial KATP channels in adenosine-enhanced ischemic preconditioning YOSHIYA TOYODA, INGEBORG FRIEHS, ROBERT A. PARKER, SIDNEY LEVITSKY, AND JAMES D. MCCULLY Division of Cardiothoracic Surgery and Biometrics Center, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02115 Received 22 February 2000; accepted in final form 9 June 2000

Toyoda, Yoshiya, Ingeborg Friehs, Robert A. Parker, Sidney Levitsky, and James D. McCully. Differential role of sarcolemmal and mitochondrial KATP channels in adenosine-enhanced ischemic preconditioning. Am J Physiol Heart Circ Physiol 279: H2694–H2703, 2000.—Adenosine-enhanced ischemic preconditioning (APC) extends the protection afforded by ischemic preconditioning (IPC) by both significantly decreasing infarct size and significantly enhancing postischemic functional recovery. The purpose of this study was to determine whether APC is modulated by ATP-sensitive potassium (KATP) channels and to determine whether this modulation occurs before ischemia or during reperfusion. The role of KATP channels before ischemia (I), during reperfusion (R), or during ischemia and reperfusion (IR) was investigated using the nonspecific KATP blocker glibenclamide (Glb), the mitochondrial (mito) KATP channel blocker 5-hydroxydecanoate (5-HD), and the sarcolemmal (sarc) KATP channel blocker HMR-1883 (HMR). Infarct size was significantly increased (P ⬍ 0.05) in APC hearts with Glb-I, Glb-R, and 5-HD-I treatment and partially with 5-HD-R. Glb-I and Glb-R treatment significantly decreased APC functional recovery (P ⬍ 0.05 vs. APC), whereas 5-HD-I and 5-HD-R had no effect on APC functional recovery. HMR-IR significantly decreased postischemic functional recovery (P ⬍ 0.05 vs. APC) but had no effect on infarct size. These data indicate that APC infarct size reduction is modulated by mitoKATP channels primarily during ischemia and suggest that functional recovery is modulated by sarcKATP channels during ischemia and reperfusion.

(24–27, 38) that adenosineenhanced ischemic preconditioning (APC), in which a bolus injection of adenosine is used coincident with single-cycle ischemic preconditioning (IPC), extends and amends the cardioprotection afforded by IPC by both significantly decreasing myocardial infarct size (P ⬍ 0.05 vs. IPC) and significantly enhancing postischemic functional recovery (P ⬍ 0.05 vs. IPC) in both the isolated, perfused rabbit heart and in the in situ blood-perfused sheep heart. Recently, we showed (25) that APC-enhanced infarct size reduc-

tion is primarily modulated by adenosine receptors before ischemia, whereas APC-enhanced postischemic functional recovery is modulated by adenosine receptors both before ischemia and during reperfusion. The downstream effector of adenosine receptor activation was shown previously to be ATP-sensitive potassium (KATP) channels that have been suggested to play a central role in IPC (4, 31, 32, 39). Two KATP channel subtypes exist in the myocardium, with one subtype located in the sarcolemma (sarcKATP) and the other in the inner membrane of the mitochondria (mitoKATP) (21). SarcKATP channels are inhibited by glibenclamide and selectively inhibited by HMR-1883 (2, 3, 11, 13), whereas mitoKATP channels are inhibited by glibenclamide and specifically inhibited by 5-hydroxydecanoate (33). The involvement of KATP channels in APC cardioprotection and the relevance and specificity of these channels during ischemia and reperfusion were unknown. The purpose of this study was to determine whether the cardioprotection afforded by APC was modulated by KATP channels, to determine whether this modulation occurred before ischemia or during reperfusion, and to determine the specificity of KATP channel modulation on APC cardioprotection during ischemia and reperfusion. Our results indicate that the cardioprotection afforded by APC is modulated by KATP channels. APC myocardial infarct size reduction is completely abolished by mitoKATP channel blockade before ischemia. APC-enhanced postischemic functional recovery is not affected by mitoKATP channel blockade before ischemia and/or during reperfusion. Blockade of sarcKATP channels both before ischemia and during reperfusion significantly decreased APC-enhanced postischemic functional recovery [P ⬍ 0.05 vs APC; not significant (NS) vs. global ischemia]. These data suggest that infarct size is modulated by mitoKATP channels primarily during ischemia, whereas postischemic functional recovery is modulated by sarcKATP channels both during ischemia and reperfusion.

Address for reprint requests and other correspondence: J. D. McCully, Div. of Cardiothoracic Surgery, Beth Israel Deaconess Medical Ctr., Harvard Institutes of Medicine, 77 Ave. Louis Pasteur, Rm. 144, Boston, MA 02115 (E-mail: [email protected]).

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked ‘‘advertisement’’ in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

stunning; myocardial protection; ATP-sensitive potassium channels

WE REPORTED PREVIOUSLY

H2694

0363-6135/00 $5.00 Copyright © 2000 the American Physiological Society

http://www.ajpheart.org

KATP CHANNELS, INFARCT SIZE, AND FUNCTIONAL RECOVERY METHODS

Animals and chemicals. New Zealand White rabbits (n ⫽ 95; 15–20 wk, 3–4 kg) were obtained from Millbrook Farm (Amherst, MA). All animals were housed individually and provided with laboratory chow and water ad libitum. All experiments were approved by the Beth Israel Deaconess Medical Center Animal Care and Use Committee and the Harvard Medical Area Standing Committee on Animals (Institutional Animal Care and Use Committee) and conformed to the National Institutes of Health guidelines regulating the care and use of laboratory animals (NIH publication 5377–3, 1996). Langendorff perfusion. All rabbits were anesthetized with ketamine (33 mg/kg) and xylazine (16 mg/kg) and received heparin (200 U/kg) intravenously via a marginal ear vein (28, 40). The heart was excised and placed in a 4°C bath of Krebs-Ringer solution equilibrated with 95% O2-5% CO2 (pH 7.4 at 37°C), in which spontaneous beating ceased within a few seconds (26, 27). Langendorff retrograde perfusion was performed as previously described (26, 27). In brief, a latex balloon containing a catheter-tip transducer (Millar Instruments, Houston, TX) was inserted into the left ventricle and held in place by a purse-string suture. The volume of the water-filled balloon was maintained at a constant physiological end-diastolic pressure in the range of 5–10 mmHg using a calibrated microsyringe. The aorta was cannulated with a metal cannula, and the heart was subjected to Langendorff retrograde perfusion at a constant pressure of 75 cmH2O at 37°C. Hearts were paced via the right atrium at 180 ⫾ 3 beats/min throughout the experiment using a Medtronic model 5330 stimulator (Medtronic, Minneapolis, MN). Hemodynamic variables were acquired using the PO-NE-MAH digital data acquisition system (Gould, Valley View, OH) with an Acquire Plus processor board and left ventricular pressure analysis software. Experimental protocol. Hearts were perfused for 18 min to establish equilibrium hemodynamics. Equilibrium was ended when heart rate, coronary flow, and left ventricular peak developed pressure (LVPDP) and end-diastolic pressure (LVEDP) had been maintained at the same level for three continuous measurement periods timed 5 min apart. Control hearts (n ⫽ 8) were perfused without global ischemia at 37°C for 180 min. Global ischemia hearts (GI; n ⫽ 8) were subjected to 30-min global ischemia and 120-min reperfusion. Global ischemia was achieved by cross-clamping the perfusion line. APC hearts (n ⫽ 8) received a 10-ml bolus injection of 1 mM adenosine in Krebs buffer (Adenoscan; Medco, Research Triangle Park, NC) coincident with IPC (5-min zeroflow global ischemia followed by 5-min reperfusion). The bolus was injected into the aortic root via the sidearm of a cannula located proximal to the perfusion cannula. Effect of KATP channel blockers on functional recovery. To distinguish the effect of glibenclamide, 5-hydroxydecanoate, and HMR-1883 on APC cardioprotection from the persistent drug effect of glibenclamide, 5-hydroxydecanoate, and HMR1883, control hearts were perfused separately with glibenclamide, 5-hydroxydecanoate, HMR-1883, or both 5-hydroxydecanoate and HMR-1883. Blockers were perfused for 7 min before global ischemia (from 18–20 min of perfusion to 25–30 min of perfusion) and for 2 min at the onset of reperfusion (R; 60–62 min of perfusion) (control⫹Glb/Glb-R, n ⫽ 3; control⫹5-HD/5-HD-R, n ⫽ 3; control⫹HMR/HMR-R, n ⫽ 3). In 5-HD-HMR/HMR-R hearts (n ⫽ 3), 5-hydroxydecanoate and HMR-1883 were perfused for 7 min before global ischemia and HMR-1883 was perfused for 2 min at the onset of reperfusion.

H2695

Role of KATP channels in APC cardioprotection during ischemia and reperfusion. To determine the role of KATP channels in APC cardioprotection during ischemia and reperfusion, APC hearts were perfused separately with the nonselective KATP channel blocker glibenclamide (18 ␮M in Krebs-Ringer solution; Sigma Chemical, St. Louis, MO) for 2 min before APC and during the 5-min reperfusion before global ischemia (Glb; n ⫽ 6) or for 2 min at the onset of reperfusion (Glb-R; n ⫽ 5). The concentration of glibenclamide was determined based on preliminary investigations using serial glibenclamide concentrations based on the data of Hoag et al. (17). A separate group of APC hearts were perfused with glibenclamide for 2 min before APC and during the 5-min reperfusion before global ischemia and for 2 min at the onset of reperfusion (Glb/Glb-R; n ⫽ 6). Role of specific KATP channels in APC cardioprotection during ischemia and reperfusion. To determine the role of mitoKATP channels in APC cardioprotection during ischemia and reperfusion, APC hearts were perfused separately with the rabbit heart selective mitoKATP channel blocker 5-hydroxydecanoate (200 ␮M, in Krebs-Ringer solution; Research Biochemicals, Natick, MA) for 2 min before APC and during the 5-min reperfusion before global ischemia (APC⫹5-HD; n ⫽ 6) or for 2 min at the onset of reperfusion (APC⫹5-HD-R; n ⫽ 6) (21). A separate group of APC hearts were perfused with 5-hydroxydecanoate (200 ␮M in Krebs-Ringer solution) for 2 min before APC and during the 5-min reperfusion before global ischemia and for 2 min at the onset of reperfusion (APC⫹5-HD/5-HD-R; n ⫽ 6). To determine the role of sarcKATP channels in APC cardioprotection during ischemia and reperfusion, APC hearts were perfused separately with the selective sarcKATP channel blocker HMR-1883 (50 ␮M in Krebs-Ringer solution; the kind gift of H. C. Englert, Hoechst-Marion-Roussel, Frankfurt, Germany) for 2 min before APC and during the 5-min reperfusion before global ischemia (APC⫹HMR; n ⫽ 6) or for 2 min at the onset of reperfusion (APC⫹HMR-R; n ⫽ 6) (2, 3, 11, 13). A separate group of APC hearts was perfused with HMR-1883 (50 ␮M, in Krebs-Ringer solution) for 2 min before APC and during the 5-min reperfusion before global ischemia and for 2 min at the onset of reperfusion (APC ⫹ HMR/HMR-R; n ⫽ 6). A final group of APC hearts was perfused with 5-hydroxydecanoate (200 ␮M, in Krebs-Ringer solution) and HMR-1883 (50 ␮M, in Krebs-Ringer solution) for 2 min before APC and during the 5 min after APC, before global ischemia, and with HMR-1883 (50 ␮M, in KrebsRinger solution) for 2 min at the onset of reperfusion (APC⫹5-HD-HMR/HMR-R; n ⫽ 6). Measurement of infarct size. Infarct size was determined as previously described using 1% triphenyltetrazolium chloride (Sigma Chemical) in phosphate buffer (pH 7.4) (18, 24, 26, 41). Left ventricle area and the area of infarcted tissue were measured by an independent, blinded observer using computer planimetry as previously described (24–27, 37, 38). Wet weight-to-dry weight ratios. Left ventricular tissue samples (⬃0.1 g) from all experimental groups were weighed (wet weight), dried at 80°C for 24 h for reweighing (dry weight), and then used for the determination of wet-to-dry weight ratios using previously described methods (26, 27). Statistical analysis. Statistical analysis was performed using SAS (version 6.12; SAS Institute, Cary, NC). Means ⫾ SE are reported in Tables 1–4 and in text. Statistical significance was assessed using repeated-measures analysis of variance with group as a between-subjects factor and time as a within-subjects factor. If this overall test was significant, one-way analysis of variance was performed at individual time points, and, when significant, post hoc comparisons

H2696

KATP CHANNELS, INFARCT SIZE, AND FUNCTIONAL RECOVERY

were made between groups at a time point. Dunnett’s test was used for comparisons between APC and other groups, because the primary focus was determination of which of the KATP treatments were different from APC. Dunnett’s test adjusts for the number of tests being performed but does not adjust for comparisons across all groups. Bonferroni correction was used for comparisons between groups other than APC. One-way analysis of variance was used for area of infarction. P ⬍ 0.05 was used for statistical significance. RESULTS

Effect of KATP channel blockers on functional recovery. The results shown in Table 1 indicate that LVPDP and the positive first derivative of pressure over time (⫹dP/dt) were significantly decreased and LVEDP was significantly increased in control⫹Glb/Glb-R, control⫹5-HD/5-HD-R, control⫹HMR/HMR-R, and control⫹5-HD-HMR/HMR-R hearts (P ⬍ 0.05 vs. control and APC) at 20 min of perfusion and at 30 min of perfusion (after perfusion of KATP channel blockers). No significant difference in LVPDP, LVEDP, ⫹dP/dt, or coronary flow was observed within or between groups during 120-min reperfusion (NS vs. control and APC, Table 1).

Infarct size was 2.5 ⫾ 0.5% in control⫹Glb/Glb-R, 2.2 ⫾ 0.5% in control⫹5-HD/5-HD-R, 1.7 ⫾ 0.2% in control⫹HMR/HMR-R, and 1.4 ⫾ 0.3% in control⫹5HD-HMR/HMR-R hearts. No significant difference in infarct size was observed within or between groups, and there was no significant difference between groups compared with control. Equilibrium hemodynamics. No significant difference in LVPDP, ⫹dP/dt, or coronary flow was observed within or between groups at the end of equilibrium (18 min of perfusion) (Tables 2–4). Role of KATP channels in APC cardioprotection during ischemia and reperfusion. LVPDP and ⫹dP/dt were significantly decreased in APC⫹Glb hearts (P ⬍ 0.05 vs. APC and APC⫹Glb-R) at 20 min of perfusion (after 2-min perfusion of glibenclamide before APC; Table 2). After APC (30 min of perfusion), LVPDP and ⫹dP/dt were significantly decreased in APC⫹Glb hearts (P ⬍ 0.05 vs. APC and APC⫹Glb-R). No significant difference in coronary flow was observed within or between groups at 30 min of perfusion, just before global ischemia. LVPDP, ⫹dP/dt, and coronary flow were significantly decreased in GI hearts (P ⬍ 0.05 vs. APC)

Table 1. Functional data for control hearts perfused with KATP channel blockers Time, min 18

20

30

Control Control⫹Glb/Glb-R Control⫹5-HD/5-HD-R Control⫹HMR/HMR-R Control⫹5-HD-HMR/HMR-R

105.6 (3.9) 112 (2.9) 108 (2.6) 105 (2.6) 107 (4.0)

105.6 (3.9) 47.3 (9.8)* 50.7 (1.5)* 55.3 (2.3)* 54.0 (2.5)*

110.1 (5.9) 54.7 (5.5)* 44.7 (1.5)* 59.3 (2.3)* 60.0 (3.8)*


6.8 (0.8) 5.3 (1.2) 5.3 (0.7) 6.0 (0.6) 6.3 (0.7)

6.8 (0.8) 17.7 (2.9)* 24.7 (2.3)* 21.7 (1.2)* 23.3 (1.2)*

6.8 (0.8) 18.3 (1.9)* 22.3 (0.7)* 17.3 (1.8)* 16.3 (1.8)*


1,405 (58) 1,735 (225) 1,558 (82) 1,548 (25) 1,483 (25)

1,414 (55) 905 (148)* 870 (22)* 908 (47)* 719 (48)*

1,407 (56) 942 (73)* 814 (12)* 894 (57)* 800 (49)*


44.3 (2.6) 52.0 (3.6) 48.0 (1.2) 51.0 (1.7) 47.0 (1.0)

45.9 (1.7) 41.0 (4.4) 39.7 (2.9) 42.0 (1.7) 40.0 (2.7)

70

80

90

120

180

114.9 (5.7) 97.3 (3.4) 95.7 (1.5) 102 (2.3) 104 (5.7)

115.0 (5.9) 105 (3.5) 99.7 (2.0) 104 (1.8) 103 (5.8)

113.6 (5.7) 107 (4.5) 98.7 (0.9) 104 (1.9) 105 (5.2)

106.9 (6.9) 106 (4.4) 95.7 (0.3) 101 (2.1) 99.3 (3.0)

95.0 (5.5) 102 (4.4) 90.0 (2.3) 95 (1.5) 91.3 (3.2)

5.4 (0.3) 5.3 (0.7) 4.0 (1.7) 4.7 (1.9) 4.7 (0.9)

5.4 (0.5) 5.7 (0.3) 4.3 (1.5) 4.3 (1.8) 4.7 (0.9)

7.0 (0.8) 5.0 (1.0) 4.3 (1.5) 4.3 (1.8) 4.7 (0.9)

8.0 (0.8) 4.7 (1.9) 5.7 (0.9) 5.0 (2.0) 5.3 (0.3)

1,712 (134) 1,706 (259) 1,450 (83) 1,547 (40) 1,502 (62)

1,592 (114) 1,776 (269) 1,468 (72) 1,499 (43) 1,511 (71)

1,516 (90) 1,798 (288) 1,447 (40) 1,567 (22) 1,461 (69)

1,433 (100) 1,683 (243) 1,402 (87) 1,461 (34) 1,251 (77)

44.8 (2.4) 45.3 (1.5) 45.0 (1.7) 50.0 (2.7) 48.0 (3.0)

44.1 (2.2) 47.0 (2.7) 46.0 (1.0) 51.0 (3.5) 47.3 (1.9)

44.4 (2.0) 49.0 (3.6) 44.0 (1.0) 49.0 (2.7) 47.7 (1.8)

42.4 (2.7) 46.0 (2.7) 43.0 (1.0) 47.0 (3.6) 42.0 (1.7)

LVPDP, mmHg

LVEDP, mmHg 5.3 (0.8) 5.0 (1.0) 4.3 (2.2) 5.3 (1.7) 4.7 (0.9)

⫹dP/dt, mmHg/s 1,561 (104) 1,595 (223) 1,349 (99) 1,430 (60) 1,451 (46)

Coronary flow, ml/min 44.6 (1.9) 40.0 (5.3) 38.7 (3.8) 37.0 (4.0) 37.0 (2.7)

42.9 (2.1) 42.0 (1.7) 45.0 (1.7) 48.0 (3.5) 43.7 (0.9)

Results are shown as means ⫾ SE; n ⫽ 3 for each group. Functional data for control hearts perfused separately with the nonselective ATP-sensitive potassium (KATP) channel blocker glibenclamide (Glb), the rabbit heart selective mitochondrial KATP (mitoKATP) channel blocker 5-hydroxydecanoate (5-HD), and the selective sarcolemmal KATP (sarcKATP) channel blocker HMR-1883 (HMR) are shown. Blockers were perfused for 7 min before global ischemia and for 2 min at the onset of reperfusion (R). In Control⫹5-HD-HMR/HMR-R hearts, 5-HD and HMR-1883 were perfused for 7 min before global ischemia and HMR-1883 was perfused for 2 min at the onset of reperfusion. Significant differences at P ⬍ 0.05 vs. control are noted with an asterisk. There was no significant difference in left ventricular (LV) peak developed pressure (LVPDP), LV end-diastolic pressure (LVEDP), positive first derivative of pressure over time (⫹dP/dt), or coronary flow observed within or between groups during 120-min reperfusion (70–180 min of perfusion).

H2697


Table 2. Functional data for control, global ischemia, and APC hearts and Glb-perfused APC hearts Time, min Group

18

20

30

70

Control GI APC APC⫹Glb APC⫹Glb-R APC⫹Glb/Glb-R

105.6 (3.9) 109.4 (6.0) 119.9 (4.7) 112.2 (1.2) 112.8 (3.1) 111.0 (2.2)

105.6 (3.9) 109.4 (6.0) 119.9 (4.7) 56.5 (4.2)* 112.8 (3.1) 62.3 (5.7)*

110.1 (5.9) 109.4 (6.0) 100.1 (4.1) 33.2 (9.0)* 76.4 (3.5)* 53.3 (3.0)*


6.8 (0.8) 7.1 (0.6) 5.1 (0.4) 6.0 (0.4) 6.2 (0.6) 5.3 (0.3)

6.8 (0.8) 7.1 (0.6) 5.1 (0.4) 21.8 (2.2)* 6.2 (0.6) 24.8 (2.9)*

6.8 (0.8) 7.1 (0.6) 3.3 (0.8) 28.0 (4.0)* 5.6 (1.0) 22.8 (2.8)*


1,405 (58) 1,556 (135) 1,696 (77) 1,637 (111) 1,597 (64) 1,506 (68)

1,414 (55) 1,556 (135) 1,696 (77) 815 (66)* 1,597 (64) 812 (62)*

1,407 (56) 1,556 (135) 1,520 (97) 635 (115)* 934 (20)* 765 (38)*


44.3 (2.6) 40.6 (2.8) 47.1 (2.5) 46.3 (3.9) 51.8 (2.1) 51.8 (3.8)

45.9 (1.7) 37.3 (2.5)* 45.6 (1.3) 48.3 (1.4) 51.8 (2.1) 40.0 (2.4)

44.6 (1.9) 30.9 (2.7)* 47.0 (2.3) 43.2 (1.9) 67.6 (1.6)* 40.3 (2.2)

80

90

120

180

115.0 (5.9) 52.0 (5.5)* 95.3 (3.8) 42.0 (11.4)* 66.0 (4.2)* 52.3 (6.0)*

113.6 (5.7) 49.9 (6.7)* 102.0 (4.6) 47.7 (11.4)* 80.4 (3.9) 64.2 (6.0)*

106.9 (6.9) 44.4 (7.1)* 102.3 (4.8) 61.3 (11.9)* 89.0 (2.8) 70.0 (5.0)*

95.0 (5.5) 37.1 (7.6)* 96.3 (4.2) 63.0 (9.9)* 80.6 (0.9) 59.2 (4.6)*

5.4 (0.3) 28.0 (3.4)* 5.0 (0.3) 22.8 (10.1)* 5.0 (1.3) 12.7 (1.4)

5.4 (0.5) 28.0 (3.2)* 6.1 (0.4) 22.3 (10.2)* 4.8 (1.2) 11.3 (1.2)

7.0 (0.8) 29.0 (3.8)* 6.6 (0.6) 17.8 (8.6) 4.8 (0.8) 10.3 (0.6)

8.0 (0.8) 32.4 (2.5)* 7.0 (0.5) 15.5 (7.4) 4.2 (1.2) 14.2 (0.6)

1,592 (114)* 901 (66)* 1,957 (101) 1,166 (103)* 1,460 (74)* 1,045 (95)*

1,516 (90) 881 (96)* 1,833 (121) 1,332 (142)* 1,642 (104) 1,158 (62)*

1,433 (100) 743 (112)* 1,651 (141) 1,162 (93)* 1,446 (67) 978 (36)*

44.1 (2.2) 25.5 (2.4)* 44.8 (1.7) 28.7 (3.9)* 39.6 (2.2) 38.0 (4.5)

44.4 (2.0) 22.5 (2.1)* 43.1 (1.9) 34.5 (5.2) 42.4 (1.8) 41.7 (3.1)

42.4 (2.7) 18.4 (2.5)* 38.6 (2.5) 30.5 (5.1) 39.6 (2.1) 33.5 (1.0)

LVPDP, mmHg 114.9 (5.7)* 49.8 (5.8) 73.6 (3.3) 27.0 (7.6)* 43.0 (3.4)* 32.8 (5.3)* LVEDP, mmHg 5.3 (0.8) 22.0 (2.9)* 5.4 (0.5) 11.3 (6.6) 4.4 (1.4) 13.3 (1.7)

⫹dP/dt, mmHg/s 1,561 (104) 662 (100)* 1,386 (62) 805 (46)* 715 (52)* 509 (46)*

1,712 (134) 771 (93)* 1,839 (113) 1,153 (92)* 1,175 (71)* 830 (93)*

Coronary flow, ml/min 42.9 (2.1) 24.9 (3.2)* 45.4 (2.0) 27.3 (2.7)* 38.0 (2.4) 23.7 (3.9)*

44.8 (2.4) 27.5 (2.4)* 45.4 (1.9) 27.0 (3.6)* 37.0 (2.5) 30.2 (4.0)*

Results are shown as means ⫾ SE; n ⫽ 5–8 for each group. Functional data after equilibrium (18-min of perfusion), during adenosine-enhanced ischemic preconditioning (APC; 20- to 30-min perfusion; 5-min ischemia and 5-min reperfusion), during global ischemia (40–60 min of perfusion), and during reperfusion (70–180 min of perfusion), for control, global ischemia (GI), APC hearts, and APC hearts perfused with the nonselective KATP channel blocker Glb for 2 min before APC and during the 5 min after APC, before GI (APC⫹GLB) or for 2 min at the onset of reperfusion (APC⫹GLB-R), or during both periods (APC⫹GLB/GLB-R) are shown. Significant differences at P ⬍ 0.05 vs. APC are noted with an asterisk.

during reperfusion (70–180 min of perfusion). LVPDP and ⫹dP/dt were significantly decreased in APC⫹Glb hearts (P ⬍ 0.05 vs. APC) throughout reperfusion (70– 180 min of perfusion). Coronary flow was significantly decreased in APC⫹Glb hearts (P ⬍ 0.05 vs. APC) at 70–90 min of perfusion. In APC⫹Glb-R hearts, LVPDP was significantly decreased (P ⬍ 0.05 vs. APC) at 70–80 min of perfusion but was not significantly different from that observed in APC at 90–180 min of perfusion. LVPDP and ⫹dP/dt were significantly decreased in APC⫹Glb/Glb-R hearts (P ⬍ 0.05 vs. APC) throughout reperfusion (70–180 min of perfusion). No significant difference was observed between control and APC hearts. Infarct size expressed as a percentage of ventricular volume was significantly increased to 32.9 ⫾ 5.1% in GI hearts (P ⬍ 0.05 vs. control and APC) compared with 1.0 ⫾ 0.3% in control hearts and 2.8 ⫾ 0.5% in APC hearts after 30 min of normothermic global ischemia and 120 min of reperfusion (Fig. 1). Infarct size was significantly increased to 22.4 ⫾ 4.3% in APC⫹Glb hearts and 28.8 ⫾ 1.1% in APC⫹Glb/Glb-R hearts (P ⬍

Fig. 1. Infarct size expressed as a percentage of ventricular volume after 30 min of global ischemia and 120 min of reperfusion in control, global ischemia (GI), and adenosine-enhanced ischemic preconditioning (APC) hearts and APC hearts perfused with the nonselective ATP-sensitive potassium (KATP) channel blocker glibenclamide for 2 min before APC and during the 5 min of reperfusion before global ischemia (APC⫹Glb), for 2 min at the onset of reperfusion (APC⫹Glb-R), or during both periods (APC⫹Glb/Glb-R). Results are shown as means ⫾ SE; n ⫽ 5–8 for each group. *Significant differences at P ⬍ 0.05 vs. APC hearts; **significant differences at P ⬍ 0.05 vs. GI hearts. There was no significant difference in infarct size between APC and control hearts.

H2698


Table 3. Functional data for APC hearts perfused with 5-HD Time, min Group

18

20

30

70

APC APC⫹5-HD APC⫹5-HD-R APC⫹5-HD/5-HD-R

119.9 (4.7) 121.0 (3.8) 119.5 (4.2) 112.5 (3.4)

119.9 (4.7) 60.8 (10.5)* 119.5 (4.2) 63.5 (9.1)*

100.1 (4.1) 64.7 (18.3)* 87.3 (5.1) 65.2 (6.9)*

80

90

120

180

LVPDP, mmHg 73.6 (3.3) 55.7 (3.1)* 56.8 (2.7)* 57.3 (6.4)*

95.3 (3.8) 79.5 (4.1) 74.8 (5.4)* 69.7 (6.3)*

102.0 (4.6) 93.2 (5.1) 89.5 (6.1) 79.8 (6.0)

102.3 (4.8) 94.3 (5.1) 92.5 (3.7) 86.7 (3.7)

96.3 (4.2) 95.7 (4.5) 84.0 (5.7) 79.3 (2.2)*

5.0 (0.3) 8.5 (2.0) 9.5 (2.4) 5.8 (0.7)

6.1 (0.4) 7.7 (1.8) 8.7 (2.2) 6.3 (0.8)

6.6 (0.6) 7.0 (1.7) 6.3 (1.7) 6.0 (0.8)

1,839 (113) 1,588 (114) 1,383 (77)* 1,094 (128)*

1,957 (101) 1,885 (145) 1,627 (111) 1,349 (140)*

1,833 (121) 1,899 (142) 1,589 (77) 1,362 (108)*

1,651 (141) 1,792 (163) 1,467 (134) 1,178 (57)*

45.4 (1.9) 42.5 (2.9) 40.3 (2.8) 41.2 (2.8)

44.8 (1.7) 43.7 (3.0) 41.3 (3.2) 43.2 (2.4)

43.1 (1.9) 42.0 (3.3) 40.0 (2.4) 45.5 (3.9)

38.6 (2.5) 42.2 (3.9) 36.8 (2.7) 41.7 (4.6)

LVEDP, mmHg APC APC⫹5-HD APC⫹5-HD-R APC⫹5-HD/5-HD-R

5.1 (0.4) 7.7 (0.8) 6.0 (0.7) 5.3 (0.4)

5.1 (0.4) 14.2 (2.3) 6.0 (0.7) 23.0 (5.6)*

3.3 (0.8) 16.7 (3.7)* 8.7 (1.5) 14.5 (3.4)*


1,696 (77) 1,786 (131) 1,582 (62) 1,473 (111)

1,696 (77) 892 (122)* 1,582 (62) 858 (80)*

1,520 (97) 1,222 (236) 1,119 (64) 848 (88)*


47.1 (2.5) 48.5 (2.8) 49.3 (2.6) 48.7 (2.7)

45.6 (1.3) 51.8 (3.3) 49.3 (2.6) 44.8 (2.3)

5.4 (0.5) 10.0 (1.8) 9.5 (1.9) 7.8 (0.9)

7.0 (0.5) 7.8 (1.4) 8.0 (2.2) 8.0 (1.3)

⫹dP/dt, mmHg/s 1,386 (62) 1,027 (31)* 973 (46)* 835 (73)*

Coronary flow, ml/min 47.0 (2.3) 63.5 (5.1)* 66.5 (3.3)* 55.2 (2.5)

45.4 (2.0) 51.2 (3.6) 49.0 (5.1) 47.3 (4.8)

Results are shown as means ⫾ SE; n ⫽ 6 for each group. Functional data for APC hearts perfused separately with the rabbit heart selective mitoKATP channel blocker 5-HD for 2 min before APC and during the 5-min reperfusion before global ischemia (APC⫹5-HD) or for 2 min at the onset of reperfusion (APC⫹5-HD-R) or during both periods (APC⫹5-HD/5-HD-R) are shown. Significant differences at P ⬍ 0.05 vs. APC are denoted with an asterisk. No significant differences were observed among APC⫹5-HD, APC⫹5-HD-R, or APC⫹5-HD/ 5-HD-R during 120-min reperfusion (70–180 min of perfusion).

0.05 vs. control, APC, and APC⫹Glb-R; NS vs. GI). Infarct size was 14.0 ⫾ 1.5% in APC⫹Glb-R hearts (P ⬍ 0.05 vs. APC⫹Glb, APC⫹Glb/Glb-R, APC, and GI). Wet weight-to-dry weight ratios after 180 min of perfusion were 5.02 ⫾ 0.57 in APC⫹Glb hearts, 5.46 ⫾ 0.86 in APC⫹Glb-R hearts, 7.43 ⫾ 0.17 in APC⫹Glb/ Glb-R hearts, 7.02 ⫾ 0.66 in GI hearts, 6.24 ⫾ 0.72 in control hearts, and 5.86 ⫾ 0.68 in APC hearts. There was no significant difference in wet weight-to-dry weight ratios between groups. Role of mitoKATP channels in APC cardioprotection during ischemia and reperfusion. LVPDP and ⫹dP/dt were significantly decreased in APC⫹5-HD and APC⫹5-HD/5-HD-R hearts (P ⬍ 0.05 vs. APC) at 20 min of perfusion (Table 3). After APC (30 min of perfusion), LVPDP was significantly decreased in APC⫹5-HD and APC⫹5-HD/5-HD-R hearts (P ⬍ 0.05 vs. APC), and LVEDP was significantly increased in APC⫹5-HD and APC⫹5-HD/5-HD-R hearts (P ⬍ 0.05 vs. APC and APC⫹5-HD-R). ⫹dP/dt was significantly decreased in APC⫹5-HD/5-HD-R hearts (P ⬍ 0.05 vs. APC) at 30 min of perfusion just before global ischemia. LVPDP and ⫹dP/dt were significantly decreased (P ⬍ 0.05 vs. APC) in APC⫹5-HD hearts at the start of reperfusion (70 min of perfusion), but by 20 min of reperfusion (80 min of perfusion), no significant difference was observed compared with APC hearts. LVPDP and ⫹dP/dt were significantly decreased (P ⬍ 0.05 vs APC) in APC⫹5-HD-R hearts at the start of reperfusion (70–80 min of perfusion), but by 30 min of reper-

fusion (90 min of perfusion), no significant difference was observed compared with APC hearts. LVPDP was significantly decreased in APC⫹5-HD/5-HD-R hearts at the start of reperfusion (70–80 min of perfusion) and at the end of reperfusion (180 min of perfusion). ⫹dP/dt was significantly decreased in APC⫹5-HD/5-HD-R hearts throughout 120 min of reperfusion (70–180 min of perfusion). There was no significant difference in LVEDP and coronary flow within or between groups during reperfusion (70–180 min of perfusion). Infarct size, expressed as a percentage of ventricular volume, was significantly increased to 23.7 ⫾ 1.9% in APC⫹5-HD hearts (P ⬍ 0.05 vs. APC and APC⫹5HD-R, NS vs. GI; Fig. 2). Infarct size in APC⫹5-HD-R hearts was 8.2 ⫾ 2.3% (P ⬍ 0.05 vs. GI and APC⫹5HD, NS vs. APC). Infarct size was significantly increased to 27.3 ⫾ 2.0% in APC⫹5-HD/5-HD-R hearts (P ⬍ 0.05 vs. APC and APC⫹5-HD-R, NS vs. APC⫹5-HD and GI). Wet weight-to-dry weight ratios after 180 min of perfusion were 7.35 ⫾ 0.53 in APC⫹5-HD hearts, 5.99 ⫾ 0.61 in APC⫹5-HD-R hearts, and 6.59 ⫾ 0.19 in APC⫹5-HD/5-HD-R hearts (NS vs. APC and control). Role of sarcKATP channels in APC cardioprotection during ischemia and reperfusion. LVPDP and ⫹dP/dt were significantly decreased in APC⫹HMR hearts (P ⬍ 0.05 vs. APC) at 20 min of perfusion (after 2 min of perfusion of HMR before APC; Table 4). After APC (30 min of perfusion), LVPDP and ⫹dP/dt were significantly decreased in APC⫹HMR hearts (P ⬍ 0.05 vs.

H2699


Fig. 2. Infarct size expressed as a percentage of ventricular volume in APC⫹5-hydroxydecanoate (5-HD), APC⫹5-HD-R, and APC⫹5HD/5-HD-R hearts after 30 min of global ischemia and 120 min of reperfusion. Results are shown as means ⫾ SE; n ⫽ 6 for each group. *Significant differences at P ⬍ 0.05 vs. APC hearts; **significant differences at P ⬍ 0.05 vs. GI hearts. No significant difference in infarct size was observed in APC⫹5-HD or APC⫹5-HD/5-HD-R hearts compared with GI hearts. There was no significant difference in infarct size between APC⫹5-HD-R and APC hearts.

APC). LVPDP and ⫹dP/dt were significantly decreased (P ⬍ 0.05 vs. APC) in APC⫹HMR-R hearts at the start of reperfusion (70–80 min and 70 min of perfusion, respectively), but by 90 min and 80 min of perfusion,

respectively, no significant difference compared with APC hearts was observed in APC⫹HMR-R hearts. LVPDP was significantly decreased in APC⫹HMR hearts throughout reperfusion except at the end of reperfusion (180 min of perfusion). ⫹dP/dt was significantly decreased in APC⫹HMR hearts at the start of reperfusion (70–90 min of perfusion), but by 120 min of reperfusion, no significant difference compared with APC hearts was observed in APC⫹HMR hearts. When sarcKATP channels were blocked with HMR1883 for 2 min before APC and during the 5-min reperfusion before global ischemia (HMR) and for 2 min at the onset of reperfusion (APC⫹HMR/HMR-R), LVPDP and ⫹dP/dt were significantly decreased throughout reperfusion (70–180 min of perfusion; P ⬍ 0.05 vs. APC). Combined role of mito- and sarcKATP channels in APC cardioprotection. To investigate the combined role of mito- and sarcKATP channels in APC cardioprotection, APC hearts were perfused with 5-HD and HMR1883 for 2 min before APC and during the 5-min reperfusion before global ischemia and with HMR1883 for 2 min at the onset of reperfusion (APC⫹5HD-HMR/HMR-R; Table 4). LVPDP and ⫹dP/dt were

Table 4. Functional data for APC hearts perfused with HMR-1883 Time, min Group

18

20

30

70

80

90

120

180

95.3 (3.8) 54.2 (7.1)* 72.3 (3.4)* 66.3 (7.8)* 49.2 (7.4)*

102.0 (4.6) 70.7 (7.6)* 86.5 (2.2) 73.7 (5.5)* 54.8 (6.5)*

102.3 (4.8) 83.2 (7.4)* 95.5 (2.9) 79.0 (3.5)* 62.8 (5.3)*

96.3 (4.2) 91.3 (6.5) 84.2 (8.7) 67.8 (4.8)* 53.3 (3.5)*

5.0 (0.3) 7.2 (1.2) 6.5 (2.2) 8.7 (2.5) 14.8 (5.0)

6.1 (0.4) 5.8 (1.1) 6.8 (1.7) 8.8 (2.2) 14.7 (4.8)

6.6 (0.6) 4.0 (1.3) 5.7 (1.7) 9.2 (2.0) 15.2 (5.6)

7.0 (0.5) 3.7 (1.0) 6.5 (1.8) 12.3 (3.5) 16.7 (4.8)*

1,839 (113) 1,140 (141)* 1,415 (91) 1,219 (270)* 751 (113)*

1,957 (101) 1,461 (142)* 1,734 (65) 1,307 (213)* 826 (102)*

45.4 (1.9) 42.2 (3.4) 51.2 (3.8) 37.3 (5.2) 31.8 (5.0)

44.8 (1.7) 41.3 (3.1) 47.8 (3.6) 37.0 (4.4) 32.5 (4.3)*

LVPDP, mmHg APC APC⫹HMR APC⫹HMR-R APC⫹HMR/HMR-R APC⫹5-HD-HMR/HMR-R

119.9 (4.7) 116.7 (4.0) 111.0 (3.8) 107.2 (2.6) 108.8 (2.5)

APC APC⫹HMR APC⫹HMR-R APC⫹HMR/HMR-R APC⫹5-HD-HMR/HMR-R

5.1 (0.4) 5.0 (0.8) 5.2 (0.5) 5.0 (0.4) 6.0 (0.4)

119.9 (4.7) 100.1 (4.1) 75.0 (11.3)* 54.0 (13.2)* 111.0 (3.8) 81.2 (6.3) 86.5 (7.1)* 63.7 (5.2)* 55.0 (8.0)* 39.8 (5.4)*

73.6 (3.3) 39.3 (5.4)* 48.8 (3.9)* 52.0 (7.7)* 35.5 (6.9)*

LVEDP, mmHg 5.1 (0.4) 29.0 (5.6)* 5.2 (0.5) 21.7 (2.7)* 28.7 (2.1)*

3.3 (0.8) 21.8 (6.7)* 7.3 (1.1) 12.4 (2.7) 13.3 (2.3)

1,696 (77) 1,696 (77) 1,431 (53) 910 (88)* 1,519 (88) 1,519 (88) 1,435 (52) 1,041 (119)* 1,418 (124) 706 (99)*

1,520 (97) 904 (121)* 1,178 (125) 812 (81)* 597 (100)*

5.4 (0.5) 9.2 (1.9) 6.3 (2.0) 8.0 (2.4) 15.7 (5.1)

⫹dP/dt, mmHg/s APC APC⫹HMR APC⫹HMR-R APC⫹HMR/HMR-R APC⫹5-HD-HMR/HMR-R

1,386 (62) 750 (122)* 903 (70)* 945 (198)* 550 (94)*

1,833 (121) 1,651 (141) 1,649 (104) 1,809 (158) 1,856 (96) 1,586 (210) 1,263 (108)* 992 (64)* 970 (103)* 882 (89)*

Coronary flow, ml/min APC APC⫹HMR APC⫹HMR-R APC⫹HMR/HMR-R APC⫹5-HD-HMR/HMR-R

47.1 (2.5) 50.5 (3.0) 53.5 (4.6) 49.5 (2.5) 49.0 (3.6)

45.6 (1.3) 51.7 (1.7) 53.5 (4.6) 42.4 (2.7) 40.2 (4.1)

47.0 (2.3) 49.8 (1.3) 65.7 (4.3)* 54.5 (3.1) 51.2 (2.7)

45.4 (2.0) 45.0 (3.3) 55.7 (3.6) 36.8 (7.6) 32.7 (6.2)

43.1 (1.9) 45.5 (3.3) 48.5 (3.6) 35.8 (3.0) 32.0 (3.1)*

38.6 (2.5) 42.3 (3.7) 44.3 (3.3) 29.5 (2.8) 27.0 (2.6)*

Results are shown as means ⫾ SE; n ⫽ 6 for each group. Functional data for APC hearts perfused separately with the selective sarcKATP channel blocker HMR-1883 for 2 min before APC and during the 5-min reperfusion before global ischemia (APC⫹HMR) or for 2 min at the onset of reperfusion (APC⫹HMR-R) or during both periods (APC⫹HMR/HMR-R) are shown. Functional data for APC hearts perfused with 5-HD and HMR-1883 for 2 min before APC and during the 5-min reperfusion before global ischemia and for 2 min at the onset of reperfusion (APC⫹5-HD-HMR/HMR-R) are also shown. Significant differences at P ⬍ 0.05 vs. APC are noted with an asterisk. There was no significant difference in LVPDP and ⫹dP/dt observed between APC⫹HMR/HMR-R and APC⫹5-HD-HMR/HMR-R hearts during 120-min reperfusion (70–180 min of perfusion).

H2700


significantly decreased (P ⬍ 0.05 vs. APC; NS vs. GI) throughout reperfusion (70–180 min of perfusion). No significant difference in LVPDP or ⫹dP/dt was observed between APC⫹5-HD-HMR/HMR-R and APC⫹HMR/HMR-R hearts. Infarct size was 10.6 ⫾ 1.3% in APC⫹HMR, 8.2 ⫾ 2.1% in APC⫹HMR-R, and 6.1 ⫾ 1.0% in APC⫹HMR/ HMR-R hearts (P ⬍ 0.05 vs. GI and APC⫹5-HD, NS vs. APC and APC⫹5-HD-R; Fig. 3). Infarct size was significantly increased to 24.0 ⫾ 2.8% in APC⫹5-HDHMR/HMR-R hearts (P ⬍ 0.05 vs. APC, APC⫹5-HD-R, APC⫹HMR, APC⫹HMR-R, and APC⫹HMR/HMR-R; NS vs. GI and APC⫹5-HD). Wet weight-to-dry weight ratios after 180 min of perfusion were 7.77 ⫾ 0.97 in APC⫹HMR, 7.19 ⫾ 1.00 in APC⫹HMR-R, 7.38 ⫾ 0.34 in APC⫹HMR/HMR-R, and 6.23 ⫾ 0.24 in APC⫹5-HDHMR/HMR-R hearts (NS vs. APC and control). DISCUSSION

Murry et al. (30) were the first to describe an endogenous myocardial protection, IPC, in which the imposition of one or more brief periods of ischemia (3–5 min) followed by reperfusion “preconditions” the heart such that infarct size and myocardial necrosis are significantly reduced during the subsequent induction of sublethal ischemia. The induction of endogenous myocardial protection via preconditioning would appear to be common in all species studied in reducing myocardial infarct volume (19). In previous reports (24–27, 37, 38), we showed that APC extends the cardioprotection afforded by IPC by both significantly decreasing infarct size (P ⬍ 0.05 vs. IPC) and significantly enhancing postischemic functional recovery (P ⬍ 0.05) in both the in situ and isolated, perfused rabbit heart and the in situ blood-perfused sheep heart. In this report, we have investigated the role of KATP channels in the isolated, perfused Langendorff heart model, and therefore the effects of neutrophils and plasma-borne inflammatory components on infarct size were not assessed. However, in earlier reports (see Ref. 24), we showed that the beneficial effects of APC in reducing myocardial infarct size and enhancing post-

Fig. 3. Infarct size expressed as a percentage of ventricular volume in APC⫹HMR-1883 (HMR), APC⫹HMR-R, APC⫹HMR/HMR-R, and APC⫹5-HD-HMR/HMR-R hearts after 30 min of global ischemia and 120 min of reperfusion. Results are shown as means ⫾ SE; n ⫽ 6 for each group. *Significant differences at P ⬍ 0.05 vs. APC hearts; **significant differences at P ⬍ 0.05 vs. GI hearts.

ischemic functional recovery are preserved in the in situ blood-perfused heart model, providing cardioprotection after 30-min global ischemia similar to that of cold blood cardioplegia. We (25) also showed that the cardioprotection afforded by APC occurs through the coincident and synergistic action of a bolus injection of adenosine and IPC. IPC or a bolus injection of adenosine, when used independently, decreased infarct size, but this decrease was significantly less than that achieved with APC and did not enhance postischemic functional recovery (25). Recently, we (25) showed that APC cardioprotection is modulated by adenosine receptors. Our results indicated that APC infarct size reduction was primarily modulated by adenosine receptors before ischemia, whereas significantly APC-enhanced postischemic functional recovery was modulated by adenosine receptors both before ischemia and during reperfusion (25). Previous reports indicated that the downstream effector(s) of adenosine receptor activation are the KATP channels. Gross and Auchampach (12) were the first to show that KATP channels mediated IPC and that glibenclamide and 5-hydroxydecanoate effectively counteracted these cardioprotective effects. These initial studies performed in the canine model have been repeated by numerous investigators in various animal and human models, and it has been proposed, based on KATP channel openers that mimic preconditioning and KATP channel inhibitors that block IPC, that the KATP channels are central to the mechanism(s) modulating IPC (1, 20, 29, 31, 34–36). Our results shown in Table 2 and Fig. 1 indicate that the cardioprotection afforded by APC is also modulated by KATP channels. The nonspecific KATP channel blocker glibenclamide completely blocked APC-enhanced infarct size reduction before ischemia, with infarct size in APC⫹Glb hearts being significantly increased such that no significant difference compared with GI hearts was observed. In APC⫹Glb-R hearts, infarct size was also increased, but this increase was significantly less (P ⬍ 0.05) than that in APC⫹Glb hearts and was significantly less (P ⬍ 0.05) than that observed in GI hearts. Our results also show that blockade of KATP channels either before ischemia (APC⫹Glb) or during reperfusion (APC⫹Glb-R) partially modulated postischemic functional recovery; however, when KATP channels were blocked both before ischemia and during reperfusion (APC⫹Glb/ Glb-R), APC-enhanced postischemic functional recovery was significantly decreased. These results are in agreement with our previous report (25) and that of Gross and Auchampach (12), who showed that intravenous administration of glibenclamide either before or after a single 5-min period of IPC completely abolished IPC-associated infarct size reduction in dogs. Our results also agree with those of Van Winkle et al. (39), who showed that cardioprotection provided by adenosine receptor activation was abolished by blockade of KATP channels, and with those of Toombs et al. (35, 36), who showed that in the rabbit heart both IPC and protection afforded by adenosine


pretreatment are abolished by blockade of KATP channels. Our data also extend the results observed by these groups and indicate that KATP channel blockade modulates postischemic functional recovery when used before ischemia and/or during reperfusion. Two KATP channel subtypes have been shown to exist in the myocardium, with one subtype located in the sarcolemma (sarcKATP) and the other in the inner membrane of the mitochondria (mitoKATP) (13, 21). Activation of KATP channels is hypothesized to be the consequence of ischemia-induced fall of intracellular ATP and activation of adenosine receptors (4, 5, 22, 31, 32, 42). Under normal conditions, the KATP channels are closed; this inhibition occurs by free intracellular ATP and Mg2⫹-ATP and is responsive to changes in ATP concentration produced by glycolysis but not by increases through application of exogenous ATP (14, 16). The opening of the sarcKATP channels during ischemia occurs as intracellular ATP levels fall (not extracellular ATP) and has been postulated to reduce the action potential plateau phase, reduce Ca2⫹ current, and, therefore, reduce the Ca2⫹-related energy cost of contraction (4, 32). However, Grover et al. (15) showed that when action potential duration is blocked the cardioprotective action (decreased infarct size) of the potassium channel opener cromakalim is maintained, suggesting that the sarcKATP channels play a role in cardioprotection other than that of infarct size reduction. Support for the separation of the involvement of KATP channel function in the modulation of infarct size reduction and enhanced functional recovery comes from the experiments of Garlid et al. (10) and the recent studies of Liu et al. (21), who showed that the mitoKATP channels, but not sarcKATP channels, modulate cell viability. To investigate the role of mito- and sarcKATP channels in APC cardioprotection we have used 5-hydroxydecanoate, shown to be a mitoKATP-specific channel blocker in the rabbit, and the cardioselective sarcKATP channel blocker HMR1883 (2, 3, 11, 13, 33). In previous studies by others in which the mechanism of IPC has been investigated, KATP channel blockers were perfused before IPC (1, 12, 36, 39). In our studies KATP channel blockers were perfused both before and after APC. This protocol was incorporated after initial experiments indicated that the use of KATP channel blockers only before APC had variable effects on the cardioprotection afforded by APC. We speculate that these results were caused by the bolus injection of adenosine, which competitively inhibited the action of the KATP channel blockers. Our results show that infarct size, expressed as a percentage of ventricular volume, was significantly increased to 23.7 ⫾ 1.9% in APC⫹5-HD hearts (P ⬍ 0.05 vs. APC and 5-HD-R, NS vs. GI; Fig. 2). These results indicate that mitoKATP channel blockade before ischemia (APC⫹5-HD) completely abolished APC-enhanced myocardial infarct size reduction (P ⬍ 0.05 vs. APC and APC⫹5-HD-R, NS vs. GI), whereas mitoKATP channel blockade during reperfusion (APC⫹5-HD-R) had no effect on APC-enhanced myocardial infarct size

H2701

reduction. MitoKATP channel blockade both before ischemia and during reperfusion (APC⫹5-HD/5-HD-R) also completely abolished APC-enhanced myocardial infarct size reduction (P ⬍ 0.05 vs. APC and APC⫹5HD-R, NS vs. GI). Of significance, our results shown in Table 3 indicate that APC⫹5-HD, APC⫹5-HD-R, and APC⫹5-HD/5-HD-R treatments had only transient effect on APC postischemic functional recovery (70–80 min of perfusion) and that, after 30 min of reperfusion (90 min of perfusion), there was no significant difference in LVPDP, LVEDP, or ⫹dP/dt among APC⫹5-HD, APC⫹5-HD-R, APC⫹5-HD/5-HD-R, and APC hearts. These results suggested that mitoKATP channels were involved in the mechanism modulating APC-enhanced infarct size reduction and that this modulation occurred primarily during ischemia. These results further suggested that mitoKATP channel blockade either before ischemia and/or during reperfusion had no effect on APC-enhanced postischemic functional recovery. We speculate that as infarct size is increased the effect on postischemic functional recovery is also increased. The relative level at which a stoichiometric relationship exists requires further investigation and cannot be answered in this report. Examination of the role of sarcKATP channels using the cardiospecific sarcKATP channel blocker HMR-1883 (2, 3, 11, 13) indicated that APC-enhanced postischemic functional recovery, shown in Table 4, was partially abolished by sarcKATP channel blockade before ischemia (APC⫹HMR) and partially abolished by sarcKATP channel blockade during reperfusion (APC⫹HMR-R). However, blockade of sarcKATP channels both before ischemia and during reperfusion (APC⫹HMR/HMR-R) significantly decreased APC-enhanced postischemic functional recovery throughout reperfusion (P ⬍ 0.05 vs. APC and APC⫹5-HD/5HD-R, NS vs. GI). No significant difference was observed in infarct size among APC⫹HMR, APC⫹HMR-R, and APC⫹HMR/HMR-R hearts compared with APC hearts. These results are in agreement with the findings of Garlid et al. (10) and Liu et al. (21). To confirm the role of mito- and sarcKATP channels in cardioprotection, APC hearts were perfused with 5-HD and HMR-1883 for 2 min before APC and during the 5 min after APC, before global ischemia, and with HMR1883 for 2 min at the onset of reperfusion (APC⫹5-HDHMR/HMR-R). This protocol blocked mitoKATP channels before ischemia and sarcKATP channels before ischemia and during reperfusion. Our results shown in Table 4 and Fig. 3 indicate that LVPDP and ⫹dP/dt in APC⫹5-HD-HMR/HMR-R hearts were significantly decreased (P ⬍ 0.05 vs. APC and APC⫹5-HD/5-HD-R) during reperfusion (70–180 min of perfusion), that infarct size was significantly increased in APC⫹5-HDHMR/HMR-R hearts (P ⬍ 0.05 vs. APC, APC⫹5-HD-R, APC⫹HMR, APC⫹HMR-R, and APC⫹HMR/HMR-R), and that these values were not significantly different from those observed in GI hearts. These data are in agreement with our earlier reports and confirm that using specific KATP channel blockade to block both mito- and sarcKATP channels before ischemia and

H2702


sarcKATP channels during reperfusion completely abolishes the cardioprotection afforded by APC, producing the same effects seen in GI hearts (NS vs. GI). These results also confirm that infarct size is primarily modulated before ischemia and that postischemic functional recovery is modulated both before ischemia and during reperfusion. Our results indicate that there is a separation of the mechanisms modulating infarct size and functional recovery. The separation of the involvement of KATP channel function in the modulation of infarct size reduction and enhanced functional recovery was previously suggested by Garlid et al. (10) and the recent studies of Liu et al. (21), who showed that the mitoKATP channels, but not sarcKATP channels, modulate cell viability. Our data suggest that in APC cardioprotection KATP channels (sarcKATP and mitoKATP) are opened during the preconditioning phase, in agreement with the earlier investigations of Gross and Auchampach (12) and Auchampach et al. (1), who suggested that the opening of the KATP channels not only triggers IPC but is also involved with the memory phase of IPC. Opening the sarc- and mitoKATP channels would allow for the influx of K⫹ to the cytoplasm and the mitochondrion and would attenuate cytosolic 2⫹ calcium (Cai2⫹) and mitochondrial calcium (Camito ) accumulation. The modulation of infarct size would pre2⫹ sumably occur through the modulation of Camito accumulation and the preservation of mitochondrial function. 2⫹ Increased Camito accumulation has been shown to destabilize the inner mitochondrial membrane, causing the inner membrane pore to open, which permits further movement of cations across the mitochondrial membrane (8). The opening of these pores renders the mitochondrion incapable of synthesizing ATP and has been suggested to be a key event in the process leading to myocardial cell death (23). We speculate that these events are directly related to infarct size reduction. Support for this hypothesis comes from earlier reports by us (6, 7) and the recent investigation of Fryer et al. (9), who showed that mitoKATP channels play an important role in the preservation of mitochondrial function. We speculate that the opening of the mitoKATP channels before 2⫹ ischemia effectively obviates Camito accumulation. The opening of the sarcKATP channels would allow 2⫹ for Cai2⫹ accumulation, but Camito accumulation would not occur, thus allowing for the preservation of mitochondrial function and cell integrity. Recently we showed (37) that APC has anti-stunning effects and that although the anti-infarct effects of APC are significantly extended the anti-stunning effects are transient. These data would suggest that, although the opening of sarcKATP channels during ischemia and reperfusion may allow for decreased Cai2⫹ accumulation, mechanisms other than sarcKATP channels are involved in the enhancement of postischemic functional recovery.

The authors thank Heinrich C. Englert, Hoechst-Marion-Roussel, Frankfurt, Germany, for efforts on our behalf in obtaining HMR1883 and for kind advice regarding the concentrations used. This study was supported by National Heart, Lung, and Blood Institute Grants HL-29077 and HL-59542 and by the American Heart Association. REFERENCES 1. Auchampach JA, Grover GJ, and Gross GJ. Blockade of ischemic preconditioning in dogs with the novel ATP dependent potassium channel antagonist sodium 5-hydroxydecanoate. Cardiovasc Res 26: 1054–1062, 1992. 2. Billman GE, Englert HC, and Scholkens A. HMR 1883, a novel cardioselective inhibitor of the ATP-sensitive potassium channel. II. Effects on susceptibility to ventricular fibrillation induced by myocardial ischemia in conscious dogs. J Pharmacol Exp Ther 286: 1465–1473, 1998. 3. Birincioglu M, Yang X-M, Critz SD, Cohen MV, and Downey JM. S-T segment voltage during sequential coronary occlusion is an unreliable marker of preconditioning. Am J Physiol Heart Circ Physiol 277: H2435–H2441, 1999. 4. Deutsch N, Klitzner TS, Lamp ST, and Weiss JN. Activation of cardiac ATP-sensitive K⫹ current during hypoxia: correlation with tissue ATP levels. Am J Physiol Heart Circ Physiol 261: H671–H676, 1991. 5. Downey JM, Liu GS, and Thornton JD. Adenosine and the anti-infarct effects of preconditioning. Cardiovasc Res 27: 3–8, 1993. 6. Faulk EA, McCully JD, Tsukube T, Hadlow NC, Krukenkamp IB, and Levitsky S. Myocardial mitochondrial calcium accumulation modulates nuclear calcium accumulation and DNA fragmentation. Ann Thorac Surg 60: 338–344, 1995. 7. Faulk EA, McCully JD, Tsukube T, Hadlow NC, Krukenkamp IB, Federman M, and Levitsky S. Magnesium cardioplegia enhances mRNA levels and the maximal velocity of cytochrome oxidase I in the senescent myocardium during global ischemia. Circulation 92: 405–412, 1995. 8. Frolkis VV, Frolkis RA, Mkhitarian LS, Sherchuk VG, Fraifeld VE, Vakulenko LG, and Syrouy I. Contractile function and Ca2⫹ transport system of myocardium in ageing. Gerontology 34: 64–74, 1988. 9. Fryer RM, Eells JT, Hsu AK, Henry MM, and Gross GJ. Ischemic preconditioning in rats: role of mitochondrial KATP channel in preservation of mitochondrial function. Am J Physiol Heart Circ Physiol 278: H305–H312, 2000. 10. Garlid K, Paucek P, Yarov-Yarovoy V, Murray H, Darbenzio R, D’Alonzo A, Lodge N, Smith M, and Grover G. Cardioprotective effect of diazoxide and its interaction with mitochondrial ATP-sensitive K⫹ channels: possible mechanism of cardioprotection. Circ Res 81: 1072–1082, 1997. 11. Gogelein H, Hartung J, Englert HC, and Scholkens BA. HMR 1883, a novel cardioselective inhibitor of the ATP-sensitive potassium channel. I. Effects on cardiomyocytes, coronary flow and pancreatic B-cells. J Pharmacol Exp Ther 286: 1453–1464, 1998. 12. Gross G and Auchampach J. Blockade of the ATP-sensitive potassium channels prevents myocardial preconditioning in dogs. Circ Res 70: 223–233, 1992. 13. Gross GJ and Fryer RM. Sarcolemmal versus mitochondrial ATP-sensitive K⫹ channels and myocardial preconditioning. Circ Res 84: 973–979, 1999. 14. Grover GJ. Pharmacology of ATP-sensitive potassium channel (KATP) openers in models of myocardial ischemia and reperfusion. Can J Physiol Pharmacol 75: 309–315, 1997. 15. Grover GJ, D’Alonzo AJ, Parham CS, and Darbenzio RB. Cardioprotection with the KATP opener cromakalim is not correlated with ischemic myocardial action potential duration. J Cardiovasc Pharmacol 26: 145–152, 1995. 16. Hiraoka M and Furukawa T. Functional modulation of cardiac ATP-sensitive K⫹ channels. News Physiol Sci 13: 131–137, 1998. 17. Hoag JB, Qian Y-Z, Nayeeem MA, D’Angelo M, and Kukreja RC. ATP-sensitive potassium channel mediates de-


18.

19. 20.

21. 22.

23. 24.

25.

26.

27.

28.

29.

layed ischemic protection by heat stress in rabbit heart. Am J Physiol Heart Circ Physiol 273: H2458–H2464, 1997. Jenkins DP, Pugsley WB, and Yellon DM. Ischemic preconditioning in a model of global ischemia: infarct size limitation, but no reduction of stunning. J Mol Cell Cardiol 27: 1623–1632, 1995. Lawson CS and Downey JM. Preconditioning: state of the art myocardial protection. Cardiovasc Res 27: 542–550, 1993. Lawton JS, Hsia PW, and Damiano RJ Jr. The adenosinetriphosphate-sensitive potassium-channel opener pinacidil is effective in blood cardioplegia. Ann Thorac Surg 66: 768–773, 1998. Liu Y, Sato T, O’Rourke B, and Marban E. Mitochondrial ATP-dependent potassium channels. Circulation 97: 2463–2469, 1998. Liu GS, Thornton J, Van Winkle DM, Stanlet AWH, Olson RA, and Downey JM. Protection against infarction afforded by preconditioning is mediated by A1 adenosine receptors in the rabbit heart. Circulation 84: 350–356, 1991. McCormack JG and Denton RM. Signal transduction by intramitochondrial Ca2⫹ in mammalian energy metabolism. News Physiol Sci 9: 71–76, 1994. McCully JD, Uematsu M, and Levitsky S. Adenosine enhanced ischemic preconditioning provides myocardial protection equal to that of cold blood cardioplegia. Ann Thorac Surg 67: 699–704, 1999. McCully JD, Toyoda Y, Uematsu M, Stewart RD, and Levitsky S. Differential involvement of adenosine A3 receptors during ischemia and reperfusion in providing for infarct reduction and functional recovery (Abstract). Circulation 100: I-2034, 1999. McCully JD, Uematsu M, Parker RA, and Levitsky S. Adenosine-enhanced ischemic preconditioning provides enhanced postischemic recovery and limitation of infarct size in the rabbit heart. J Thorac Cardiovasc Surg 116: 154–162, 1998. McCully JD, Uematsu M, Parker RA, and Levitsky S. Adenosine enhanced ischemic preconditioning provides enhanced cardioprotection in the aged heart. Ann Thorac Surg 66: 2037– 2043, 1998. Miura T, Goto M, Miki T, Sakamoto J, Shimamoto K, and Iimura O. Glibenclamide, a blocker of ATP-sensitive potassium channels, abolishes infarct size limitation by preconditioning in rabbits anesthetized with xylazine/pentobarbital but not with pentobarbital alone. J Cardiovasc Pharmacol 25: 531–538, 1998. Munch-Ellingsen J, Bugge E, and Ytrehus K. Blockade of the KATP-channel by glibenclamide aggravates ischemic injury, and counteracts ischemic preconditioning. Basic Res Cardiol 91: 382–388, 1996.

H2703

30. Murry CE, Jennings RB, and Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 74: 1124–1136, 1986. 31. Nichols CG and Lederer WJ. Adenosine triphosphate sensitive potassium channels in the cardiovascular system. Am J Physiol Heart Circ Physiol 261: H1675–H1686, 1991. 32. Noma A. ATP-regulated K⫹ channels in cardiac muscle. Nature 305: 147–148, 1983. 33. Sato T, O’Rourke B, and Marban E. Modulation of mitochondria ATP-dependent K⫹ channels by protein kinase C. Circ Res 83: 110–114, 1998. 34. Terzic A, Jahangir A, and Kurachi Y. Cardiac ATP-sensitive K⫹ channels: regulation by intracellular nucleotides and K⫹ channel opening drugs. Am J Physiol Cell Physiol 269: C525– C545, 1995. 35. Toombs CF, Moore TL, and Shebuski RJ. Limitation of infarct size in the rabbit by ischemic preconditioning is reversible by glibenclamide. Cardiovasc Res 27: 617–622, 1993. 36. Toombs CF, McGee DS, Johnston WE, and Vinten-Johansen J. Protection from ischemic reperfusion injury with adenosine pretreatment is reversed by inhibition of ATP sensitive potassium channels. Cardiovasc Res 27: 623–629, 1993. 37. Toyoda Y, Di Gregorio V, Parker RA, Levitsky S, and McCully JD. Anti-stunning and anti-infarct effects of adenosine enhanced ischemic preconditioning. Circulation. 102: 326–331, 2000. 38. Uematsu M, Gaudette GR, Laurikka JO, Levitsky S, and McCully JD. Adenosine-enhanced ischemic preconditioning decreases infarct in the regional ischemic sheep heart. Ann Thorac Surg 66: 382–387, 1998. 39. Van Winkle DM, Chien GL, Wolff RA, Soifer BE, Kuzume K, and Davis RF. Cardioprotection provided by adenosine receptor activation is abolished by blockade of KATP channel. Am J Physiol Heart Circ Physiol 266: H829–H839, 1994. 40. Walsh RS, Tsuchida A, Daly JJ, Thornton JD, Cohen MV, and Downey JM. Ketamine-xylazine anesthesia permits a KATP channel antagonist to attenuate preconditioning in rabbit myocardium. Cardiovasc Res 28: 1337–1341, 1994. 41. Ytrehus K, Liu Y, Tsuchida A, Miuura T, Liu GS, Yang X-M, Herbert D, Cohen MV, and Downey JM. Rat and rabbit heart infarction: effects of anesthesia, perfusion, risk zone, and method of infarct sizing. Am J Physiol Heart Circ Physiol 267: H2383– H2390, 1994. 42. Zhao Z-Q, Nakanishi K, McGee DS, Tan P, and VintenJohansen J. A1 receptor mediated myocardial infarct size reduction by endogenous adenosine is exerted primarily during ischemia. Cardiovasc Res 28: 270–279, 1994.